Certara (NASDAQ:CERT) Updates FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $391.0 million.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CERT. Robert W. Baird decreased their price objective on Certara from $19.00 to $18.00 and set a neutral rating on the stock in a report on Wednesday, August 7th. UBS Group decreased their price target on Certara from $20.00 to $16.00 and set a neutral rating on the stock in a research note on Wednesday, August 7th. JMP Securities reaffirmed a market perform rating on shares of Certara in a research note on Wednesday, July 10th. Barclays decreased their price target on Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a research note on Friday, June 28th. Finally, KeyCorp decreased their price target on Certara from $23.00 to $20.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $17.79.

Certara Price Performance

Certara stock opened at $13.16 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. The firm has a market cap of $2.12 billion, a P/E ratio of -33.74, a P/E/G ratio of 5.39 and a beta of 1.52. The business’s fifty day moving average is $14.16 and its two-hundred day moving average is $16.14. Certara has a 52 week low of $11.70 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. Certara’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Equities research analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.